Oricell Therapeutics
Updated: May 03, 2026
CEO - Helen Yang
Country: China | Funding: $418.5M (+)
Founded: 2015
Website: https://www.oricell.com/en/
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. The company’s pipeline is headed up by Ori-C101, a GPC3-targeted autologous CAR-T therapy against hepatocellular carcinoma (HCC). The biotech is now gearing up for further studies with the ultimate aim of making Ori-C101 the first globally-approved CAR-T for HCC.
Founded: 2015
Website: https://www.oricell.com/en/
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. The company’s pipeline is headed up by Ori-C101, a GPC3-targeted autologous CAR-T therapy against hepatocellular carcinoma (HCC). The biotech is now gearing up for further studies with the ultimate aim of making Ori-C101 the first globally-approved CAR-T for HCC.
